Vicore Pharma Holding AB announced the Annual General Meeting's election of two very experienced board members, Dr Elisabeth Björk and Dr Michael Buschle. Vicore held its Annual General Meeting on May 11, 2023 where Dr Elisabeth Björk and Dr Michael Buschle were elected to the Board of Directors, effective immediately. Dr Elisabeth Björk is SVP, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca, where she oversees clinical development from phase I-IV, large outcomes programs, major global filings and regulatory interactions, as well as global commercial strategy and implementation across regions and therapy areas.

Prior to joining AstraZeneca in 2002, Dr Björk spent over 15 years in clinical practice and academic research. She also has experience serving as a director on the boards of small and mid-size international life science companies. Dr Björk is board certified in internal medicine and holds a PhD in endocrinology.

Dr Michael Buschle holds a PhD from University of London and has more than 25 years' experience in basic research as well as from biotech and pharma R&D. Dr Buschle has held C-level positions at mid-size Pharma and biotech companies. Among others, Dr Buschle was a co-founder of vaccine company Intercell AG (merged with Vivalis to create Valneva in 2012) and President Biologics and Chief Scientific Officer at Glenmark Pharmaceuticals.